Repros Therapeutics (RPRX) reports six-month interim results from a study of "Androxal treatment of secondary hypogonadal men and its effect on bone mineral density."
No bone loss was observed compared to placebo.
Some improvement in bone mineral density was observed in the Androxal group.
Topline, 12-month results are due in Q2 2014. (PR)
Shares +0.9% AH.